# Session: Bridging the Gap: Addressing Unmet Clinical and Technical Needs for AI Implementation in Hepatology

**Speaker:** Dr. Pritam Nath
**Designation:** Dept. of Gastroenterology
**Organization:** KIMS, Bhubaneswar

---

## 1. Background: Growing Liver Disease Burden in India

Chronic Liver Disease (CLD) has become a major healthcare challenge worldwide, and India is now facing a burden comparable to developed countries. This increase is not limited to a single condition but spans a wide spectrum of liver diseases.

### Key contributors include:

* Cirrhosis
* Fatty liver disease (both alcohol-related and non-alcoholic, linked to obesity)
* Chronic Hepatitis B and C infections
* Liver cancer

These diseases result in **high morbidity and mortality**, leading to:

* Heavy healthcare expenses
* Loss of personal savings
* A growing burden on India’s GDP

Despite advances in medicine, mortality from cirrhosis and liver cancer has continued to rise over the last 15 years. This trend reflects a broader epidemiological shift—from infectious diseases to non-communicable diseases—similar to patterns seen in Western nations.

---

## 2. Natural History of Chronic Liver Disease (CLD)

One of the most challenging aspects of liver disease is its **slow and silent progression**.

### Disease progression stages:

1. **Initial Injury and Fibrosis**

   * Caused by long-term insults such as alcohol use, obesity, or viral infections
   * Scar tissue forms gradually
   * Liver regeneration masks early damage

2. **Cirrhosis**

   * **Compensated Cirrhosis**

     * No obvious symptoms
     * Survival: ~10–12 years
   * **Decompensated Cirrhosis**

     * Symptoms appear: jaundice, ascites, vomiting, fatigue, anorexia
     * Survival drops to less than 2 years

3. **End-Stage Liver Disease**

   * Liver transplantation is the only curative option
   * Limited by donor shortage and specialist availability

This long asymptomatic window creates a **critical opportunity for AI-based early detection**.

---

## 3. AI for Early Detection and Diagnosis

Traditional diagnostic tools face limitations:

* Simple tests → low accuracy
* Advanced tools (e.g., FibroScan) → expensive and inaccessible

AI overcomes this by **integrating multiple data sources**.

### Data used by AI models:

* Clinical data: age, gender, BMI, diabetes, alcohol use, smoking
* Laboratory data: CBC, liver and kidney function tests
* Imaging: ultrasound, CT, MRI

### Why AI helps:

* Detects subtle trends and variations invisible to clinicians
* Tracks small CBC changes over time
* Learns complex disease patterns

### Validation:

Models are trained against **gold standards**:

* Liver biopsy
* FibroScan

---

## 4. Case Study: Mayo Clinic ACE Score

* AI model trained on:

  * 5,000 cirrhotic patients
  * 20,000 healthy controls
* Input: **ECG data only**
* Output: AI Cirrhosis ECG (ACE) score
* Cost: < ₹100
* Advantage: widely available and scalable

This demonstrates AI’s ability to transform **low-cost routine tests into powerful screening tools**.

---

## 5. AI for Precision Treatment

AI supports **personalized treatment decisions**.

### Alcohol-Associated Hepatitis

* Steroids help only a subset of patients
* Others experience harm
* AI can predict:

  * Likely responders
  * Likely non-responders

### Liver Cancer Treatment

* Same disease stage ≠ same response
* AI predicts:

  * Treatment benefit
  * Toxicity risk
  * Non-response

This enables safer, more targeted therapy.

---
